Recombinant Nipah virus Glycoprotein G (G)

What is the structural organization of Nipah virus Glycoprotein G?

Nipah virus glycoprotein G possesses a distinctive globular head domain formed of a six-bladed beta sheet-propeller structure, connected to a transmembrane anchor via a flexible stalk domain. This structural arrangement facilitates receptor binding and subsequent viral entry mechanisms. The protein's tertiary structure enables it to undergo significant conformational changes during the viral attachment process .

What cellular receptors does Nipah virus Glycoprotein G interact with?

Nipah virus Glycoprotein G specifically binds to the cellular receptors ephrin B2 and ephrin B3, which serve as the primary attachment factors for viral entry. Following receptor binding, Glycoprotein G undergoes a conformational change that triggers Glycoprotein F, ultimately leading to membrane fusion between the viral envelope and host cell membrane .

How does Glycoprotein G contribute to Nipah virus pathogenicity?

Glycoprotein G plays a crucial role in virus infectivity and the induction of protective immunity. As the primary attachment protein, it determines tissue tropism by recognizing specific cellular receptors. The protein is essential for viral entry into host cells and represents a key antigenic determinant recognized by the host immune system during infection .

What expression systems are optimal for producing research-grade recombinant Nipah virus Glycoprotein G?

Based on the literature, two principal expression systems have been utilized:

Mammalian expression systems such as HEK293 cells produce recombinant Glycoprotein G with post-translational modifications similar to the native viral protein, making them preferable for functional studies . E. coli systems yield higher quantities but require solubilization and refolding procedures to obtain functional protein .

What methodologies are effective for purifying recombinant Nipah virus Glycoprotein G from inclusion bodies?

When expressed in E. coli, the extracellular domain of Nipah virus Glycoprotein G typically forms insoluble inclusion bodies. An effective purification methodology includes:

• Extraction of inclusion bodies using bacterial protein extraction reagent (B-PER)

• Multiple washing steps to remove bacterial contaminants

• Solubilization using strong denaturants (8M urea or 6M guanidine HCl)

• Affinity purification using nickel-nitrilotriacetic acid (Ni-NTA) chromatography when a hexahistidine tag is incorporated

• Controlled renaturation through gradual removal of the denaturant via dialysis

This process yields approximately 0.01-0.03 mg of purified recombinant G protein per gram of wet bacterial cells, with the purified protein showing monodispersity with a hydrodynamic radius of 14 nm .

How can epitope mapping of Nipah virus Glycoprotein G contribute to vaccine development?

Immunoinformatics approaches have identified specific peptide sequences within Glycoprotein G that demonstrate strong binding affinity to MHC class I and II alleles, making them potential candidates for epitope-based vaccines. The peptides TVYHCSAVY and FLIDRINWI have shown particularly promising results in computational analyses. When considering conservancy, binding affinity, and population coverage factors, the peptide FLIDRINWIT appears highly suitable for vaccine formulation against Nipah virus .

Researchers should employ the following methodology for epitope-based vaccine development:

• Retrieve the complete sequence of Glycoprotein G from reliable databases (e.g., NCBI)

• Utilize prediction tools such as BepiPred-2.0 for B-cell epitopes and appropriate algorithms for MHC class I and II epitopes

• Evaluate candidate peptides through molecular docking studies

• Assess epitope conservancy across viral strains

• Calculate theoretical population coverage based on HLA distribution

• Validate promising candidates through in vitro and in vivo studies

What experimental approaches can validate the immunological relevance of recombinant Nipah virus Glycoprotein G?

To validate the immunological relevance of recombinant Glycoprotein G, researchers can employ:

• Western blot analysis: Using sera from Nipah virus-infected animals to confirm antigenic recognition

• Enzyme-linked immunosorbent assay (ELISA): Developing quantitative immunoassays to detect antibodies in infected samples

• Neutralization assays: Testing if antibodies raised against the recombinant protein can neutralize viral infectivity

• T-cell activation assays: Measuring T-cell responses to the recombinant protein or derived peptides

Light scattering analysis can also confirm the structural integrity of the purified protein, with monodispersity indicating proper folding and absence of aggregation .

How can researchers address protein aggregation during Glycoprotein G expression and purification?

Protein aggregation represents a significant challenge when working with recombinant Nipah virus Glycoprotein G. Researchers can implement the following strategies:

• For E. coli expression systems:

  • Optimize induction conditions (temperature, IPTG concentration, duration)

  • Co-express molecular chaperones to facilitate proper folding

  • Use fusion partners that enhance solubility (e.g., MBP, SUMO, thioredoxin)

  • Implement a controlled refolding protocol with gradual denaturant removal

  • Include stabilizing agents such as arginine or glycerol during refolding

• For mammalian expression systems:

  • Optimize cell culture conditions and harvest timing

  • Consider using secretion signal sequences for extracellular domain expression

  • Incorporate appropriate tags for enhanced solubility and purification

What analytical methods can confirm the structural and functional integrity of purified Glycoprotein G?

Multiple complementary analytical techniques should be employed to ensure the quality of purified recombinant Glycoprotein G:

Light scattering analysis is particularly valuable, as demonstrated in previous research where purified Glycoprotein G showed monodispersity with a hydrodynamic radius (Rh) of 14 nm, indicating proper folding .

How do Glycoprotein G variants from different Nipah virus strains compare?

Researchers focusing on the Malaysia strain of Nipah virus should consider strain-specific variations in Glycoprotein G. While the core structural features remain conserved, amino acid differences between strains can affect receptor binding affinity, immunogenicity, and potential vaccine efficacy. When designing experiments, researchers should clearly identify which strain their recombinant protein represents (e.g., Malaysia strain, Bangladesh strain) and consider how strain variation might impact their research questions .

For comprehensive studies, researchers should consider comparative analyses between different strain-derived Glycoprotein G proteins to identify conserved epitopes that might serve as universal vaccine targets or diagnostic markers.

What methodologies are appropriate for cross-strain reactivity studies using recombinant Glycoprotein G?

To investigate cross-strain reactivity, researchers should:

• Express Glycoprotein G from multiple Nipah virus strains using identical expression systems

• Perform side-by-side comparisons using standardized assays

• Test reactivity with serum samples from different outbreak regions

• Conduct epitope mapping to identify conserved and variable regions

• Evaluate neutralizing antibody responses against pseudotyped viruses bearing Glycoprotein G from different strains